Global Head And Neck Cancer Therapeutics Market Report 2022: Featuring Eli Lilly, Merck, Sanofi, Takeda Pharmaceutical & More
09 janv. 2023 07h48 HE
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "Global Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type (Immunotherapy, Chemotherapy, and...
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
01 déc. 2022 07h00 HE
|
Provectus Biopharmaceuticals Inc.
50% CR and 83% ORR by RECIST 1.1 criteriaRapid CRs achieved within 15 to 27 weeksMedian PFS not reached during 2-year treatment interval; 83% PFS rate100% OS rate for CRs; ongoing after 18 to 36...
Immune Checkpoint Inhibitors Global Market Report 2022: Featuring Bristol-Myers Squibb, Merck, Novartis, Pfizer & More
29 nov. 2022 08h08 HE
|
Research and Markets
Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market, by Drug Class, By Cancer Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
Global Melanoma Cancer Market Report 2022-2028: Growing Prevalence of Melanoma Driving Sector Expansion
19 oct. 2022 08h43 HE
|
Research and Markets
Dublin, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The "Global Melanoma Cancer Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global market for...
Global Head and Neck Cancer Therapeutics Market Report 2022: Advances in Biochemistry and Genomics Fuels Sector
16 sept. 2022 08h23 HE
|
Research and Markets
Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) -- The "Head and Neck Cancer Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a...
Global Head & Neck Cancer Drugs Market (2022 to 2027) - Featuring AbbVie, Amgen and Gilead Sciences Among Others
24 août 2022 05h08 HE
|
Research and Markets
Dublin, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Head & Neck Cancer Drugs Market (2022-2027) by Drug Class, Product, End User, Geography, Competitive Analysis and the Impact of Covid-19...
World Immune-checkpoint Drugs in Oncology Analytical Handbook 2022
08 juin 2022 03h18 HE
|
Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immune-checkpoint Drugs in Oncology:...
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
08 avr. 2022 13h00 HE
|
ImCheck Therapeutics SAS
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Datafrom the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022 Continued positive safety data across a range of ICT01 doses...
Oncotelic Presenting at BiotechGate Digital Partnering
19 janv. 2022 09h05 HE
|
Oncotelic Therapeutics, Inc.
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
05 janv. 2022 08h01 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...